MSB 3.33% $1.40 mesoblast limited

early revenue MSB, page-11

  1. 4,711 Posts.
    lightbulb Created with Sketch. 721
    Over the next couple of yrs this move by Japan [the worlds #2 health care market], to embrace early stage approvals for cell based therapies, which are able to show safety and some measure of efficacy, will have global implications. It's human nature, if "Billy" can get a cell based treatment for something otherwise difficult to treat, "Johnny", "Susie", "Bobbie" and everybody else will "want one too"   and remember, contrary to what many believe, the USFDA are on the verge, of initiating a newgen approach to clinical trials, with the first to launch for brain cancer, here in Oz, next yr, so their thinking is not massively far away from streamlined approvals themselves! Also, I personally expect Obama to go all-out on regen medicine in his last 12mths in office....2016 very exciting!
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.40
Change
0.045(3.33%)
Mkt cap ! $1.592B
Open High Low Value Volume
$1.35 $1.42 $1.33 $3.802M 2.753M

Buyers (Bids)

No. Vol. Price($)
2 23940 $1.39
 

Sellers (Offers)

Price($) Vol. No.
$1.40 22571 2
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.